A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Lilly

Status and phase: Completed; Phase 2; Phase 1

Conditions: Schizophrenia

Treatments: Drug: olanzapine; Drug: placebo; Drug: atomoxetine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00089869

8269

H6U-MC-HGLM

Details and patient eligibility

About

Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have a clinical diagnosis of Schizophrenia
• Must be at least 18 years of age and not older than 55 years of age
• Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks
• Women of childbearing potential must be using a medically accepted means of contraception
• Must be able to swallow capsules

Exclusion criteria

• Has serious health problems other than Schizophrenia
• Takes an antidepressant for depression
• Takes insulin for diabetes
• Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months